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METHODS: Patient relevant endpoints of treatment (remission of depression, 
response to treatment, no relapse, serious adverse events, adverse events, social func-
tion, anxiety, pain, cognitive function) were prioritized using pairwise comparisons of 
these outcomes. In two separate groups, twelve patients and seven experts judged on 
a 9 point scale the relative importance of pairs of two outcome measures. The geo-
metric mean of these judgments was used to derive weighting factors for the outcome 
measures (scale 0–1). RESULTS: Of all outcome measures, patients rated response to 
treatment highest (0.32), while experts rated remission of depression highest (0.48). 
Adverse events were all rated lowest by patients as well as by experts, and disease-
speciﬁ c quality of life domains such as social function (0.11 & 0.09), anxiety (0.12 
& 0.05) and cognitive function (0.13 & 0.06) were rated in between. CONCLU-
SIONS: The most important outcome measures according to the patients are, in order 
of decreasing importance: response, cognitive function, no anxiety, social function, no 
relapse, no adverse events, and remission. The AHP appears to be suitable in gaining 
an overview of the importance of patient relevant outcome measures. An additional 
advantage of AHP is that the group discussions offer insight in the question why the 
endpoints are important.
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OBJECTIVES: Outcomes research in patients with schizophrenia should take into 
account the subjective interpretation of the mood and physical changes accompanying 
medication. Those changes inﬂ uence the behavioural response to treatment and ulti-
mately the patient’s clinical outcome as mediated by his treatment compliance. Our 
aim was to assess the relationship between a speciﬁ c well-being measure, the SWN-K20 
that presents a general and 5 speciﬁ c measurement subdomains (mental functioning, 
social integration, emotional regulation, physical functioning, and self-control), and 
the 8 domains of the SF-36 v1 as a general quality of life measure. METHODS: The 
validation sample for this study comprised 97 patients diagnosed with schizophrenia 
and who were rated as clinically stable at the moment of the study (1 week test-retest 
intraclass correlation coefﬁ cient for clinical symptoms = 0.96). The patients were 
recruited as part of a multicenter psychometric trial to validate the SWN-K20 in 
Spanish. The associations between the domains of the SWN-K20 and the SF-36 were 
evaluated by the Spearman’s rank correlation test. RESULTS: All correlations among 
domains were positive and most were statistically signiﬁ cant (p < 0.05). As expected 
the bodily pain domain of the SF-36 presented the lower correlations with the 
SWN-K20 (rho range of 0.10 to 0.25), whereas the other 7 domains correlated sig-
niﬁ cantly with the total SWN-K20 score (rho range 0.49 to 0.60, all p < 0.001). 
Overall the largest correlations were obtained between the SWN-K20 and the SF-36 
domains of general health (rho = 0.53), mental health (rho = 0.60), and vitality (rho 
= 0.54). CONCLUSIONS: The positive but nevertheless moderate correlations 
observed between a speciﬁ c well-being scale, as the SWN-K20, and a general quality 
of life scale, as the SF-36, supports the inclusion of speciﬁ c and diagnose-tailored 
instruments for outcome assessments of patients with schizophrenia.
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OBJECTIVES: Understand features of an electronic device that allow a marked 
improvement in the quality of collected data; the importance of improved data quality 
leading to enhanced patient safety and drug labeling; populations best suited for paired 
PRO and cognitive measurement technologies; important practical considerations for 
implementation in clinical trials including training and compliance; the potential for 
using real-time parallel data for adverse event safety monitoring. METHODS: This 
session discusses using ePRO and biometric technology for parallel data capture 
emphasizing advantages, disadvantages, execution, and ways to leverage these data. 
The session will review PRO and cognitive testing technologies, including comparisons 
of devices that combine physiological measures with a patient interface with systems 
that use separate PRO input and biometric devices. RESULTS: Assessing a treatment’s 
ability to enhance or prohibit reduction of cognitive processing efﬁ ciency is an emerg-
ing study in the pharmaceutical industry. Case studies examine how the use of cogni-
tive function tests in combination with ePRO can enhance the data collection so drug 
effects otherwise unidentiﬁ ed can be determined. The speaker will discuss the future 
of ePRO combined with biometric measurements as a standard of clinical research. 
CONCLUSIONS: Clinical trial endpoints can involve collection of physiologic and 
patient-reported outcome data; a combination of subjective and objective data. Elec-
tronic forms of information capture assure trial efﬁ ciencies including edit checks and 
shorter time to database lock. ePRO provides time-stamped, legible and complete data 
from subjects. Biometric devices capture the physiological measurements. Typically, 
cognition data have been collected from patients separately from PRO data during 
clinical trials, increasing respondent burden and risk of error such as transposing 
manually entering data. The use of ePRO and biometric devices, evolution of data 
transmission technology, and greater technologic sophistication of consumers, provide 
an opportunity for parallel electronic data capture, simultaneously capturing and 
transmitting physiologic and PRO parameters in clinical studies.
PMH57
REVIEW OF CO-MORBIDITY OF EATING AND BODY DYSMORPHIC 
DISORDERS
Faragó E, Pakai A, Dér A, Oláh A, Boncz I, Németh K
University of Pécs, Pécs, Hungary
OBJECTIVES: Our intention was to investigate the prevalence of Eating Disorder and 
Body Dysmorphic Disorder in patients diaghnosed with depression, anxietay and 
borderline personality disorder by gender, using controll groups. METHODS: The 
reserach was 2009 at the Department of Phsyciatry of Szigetvár Hospital (Hungary). 
Eating Disorder Inventory was used. a self-made questionnaire aimed the body mass, 
body height and several demographic data. Inclusion criteria: ones between 18 and 
50 years age, and according to BNO F32-F34 (depression), F41 (anxiety), F6030 
(borderline personality disorder) diagnoses. Control group: participants with age 
between 18 and 50 years like that, who do not stand under a psychiatric treatment. 
The statistical analysis consisted of two sample T test, χ2-probe. RESULTS: The target 
group’s number was 82, the control group 85. In the “The feeling of the insufﬁ ciency” 
(P < 0.001), “Interpersonal distrust” (P < 0.005), “Interoceptive consciousness” (P < 
0.001) scales, the members of the control group from all three psychiatric patient 
groups reached a signiﬁ cantly lower score away. In the “Bulimia” scale there was a 
signiﬁ cantly lower score in the control group as well than the borderline in a group 
(P < 0.005), and here I found a signiﬁ cant difference between the members of two 
psychiatric groups: the anxious group reached a lower score, compared with the 
borderline group (P < 0.001). CONCLUSIONS: The three psychiatric patient groups 
did not attain the threshold value onto one of the eating disturbances relevant scales 
neither There is not a direct, causal contact between the examined psychiatric clinical 
pictures. The men’s higher result achieved on the „Bulimia” scale relates rather onto 
the binge eating disorder.
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OBJECTIVES: The primary objective of this analysis was to compare ﬁ ve different 
clinical measures and their impact on economic modelling. Clinical measures com-
pared are the Mini-Mental State Examination (MMSE), the Cognitive Component 
Score (CCS), the Functional Component Score (FCS) the Behaviour Component Score 
(BCS), and the Dependence Scale (DS). METHODS: The MMSE, CCS, FCS, BCS and 
DS were compared in their ability to explain variation in clinical outcomes, economic- 
and other utilized resources, caregiver burden (Zarit Scale) and caregiver QoL 
(EQ-5D) using univariate (Pearson correlations) and multivariate (linear regression) 
analyses. Data on subjects and caregivers was obtained from multiple centres in Spain. 
RESULTS: In total 394 subjects, males and females aged 50 to 93 years old with mild 
cognitive impairment to severe dementia were included in this study. CCS, FCS, BCS 
and DS were moderately correlated with MMSE, with Pearson correlations ranging 
from −0.26 for BCS to −0.56 for CCS. These four clinical measures were also mod-
erately correlated with medical costs, Zarit Scale and EQ-5D while MMSE was not. 
These measures also performed better in explaining variation in medical costs, Zarit 
Scale and caregivers’ EQ-5D. MMSE performed better explaining variation in the 
number of concomitant conditions and caregiver time (hours per day). CONCLU-
SIONS: The CCS, FCS, BCS and DS are better predictors in modelling AD progression 
on a higher number of variables including medical costs, caregivers’ burden and 
caregivers QoL than the MMSE.
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OBJECTIVES: Aripiprazole has been claimed to have a beneﬁ cial effect on cognition 
with an emphasis on verbal functioning in schizophrenic patients. a prospective, 
multicenter, open-label study of Aripiprazole was set to evaluate the effect on quality 
of life, in relation to illness severity and cognitive functioning of a treatment with 
aripiprazole in schizophrenic patients. METHODS: A total of 363 schizophrenic 
patients from 18 to 65 years, treated with different typical and atypical antipsychotics 
or had no previous treatment, were switched to aripiprazole after a 2 week washout 
period. Quality of life was assessed by use of the Quality of Life Enjoyment and 
Satisfaction Questionnaire (QLESQ) at 3 separate test moments in a 12 weeks period. 
